ABBV
AbbVie Inc. NYSE Listed Jan 2, 2013$216.63
-2.08%
vs $221.23
Mkt Cap $382.7B
52w Low $181.73
55.3% of range
52w High $244.81
50d MA $211.67
200d MA $220.54
P/E (TTM)
91.4x
EV/EBITDA
24.9x
P/B
—
Debt/Equity
-21.1x
ROE
-55.5%
P/FCF
21.6x
RSI (14)
48.70
ATR (14)
$5.23
Beta
0.36
50d MA
$211.67
200d MA
$220.54
Avg Volume
5.5M
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
1 North Waukegan Road · North Chicago, IL 60064-6400 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | BMO | 2.59 | 2.65 | +2.3% | 197.69 | -2.9% | +3.1% | +3.6% | -2.2% | +0.8% | -1.0% | — |
| Feb 4, 2026 | BMO | 2.65 | 2.71 | +2.3% | 225.66 | -7.0% | -3.8% | +0.9% | +2.0% | -0.1% | -0.4% | — |
| Oct 31, 2025 | BMO | 1.77 | 1.86 | +5.1% | 228.20 | -2.3% | -4.5% | -2.8% | +1.9% | +0.4% | +1.0% | — |
| Jul 31, 2025 | BMO | 2.88 | 2.97 | +3.1% | 189.31 | +4.1% | -0.2% | +3.3% | +1.0% | +0.7% | -1.1% | — |
| Apr 25, 2025 | BMO | 2.38 | 2.46 | +3.4% | 180.37 | +3.7% | +3.2% | +3.4% | +0.6% | +0.8% | -0.9% | — |
| Jan 31, 2025 | BMO | 2.98 | 2.16 | -27.5% | 175.65 | +6.6% | +4.7% | +3.4% | -0.1% | +0.9% | +0.6% | — |
| Oct 30, 2024 | BMO | 2.92 | 3.00 | +2.7% | 189.45 | +1.1% | +6.4% | +1.2% | -0.2% | -1.5% | +0.6% | — |
| Jul 25, 2024 | BMO | 2.57 | 2.65 | +3.1% | 176.21 | +0.4% | +3.4% | +1.6% | -1.7% | +2.7% | -0.8% | — |
| Apr 26, 2024 | BMO | 2.26 | 2.31 | +2.2% | 167.29 | -0.1% | -4.6% | +1.2% | +0.7% | -0.6% | -0.6% | — |
| Feb 2, 2024 | BMO | 2.76 | 2.79 | +1.1% | 167.59 | +1.1% | +0.6% | +1.5% | +1.2% | +1.0% | -0.1% | — |
| Oct 27, 2023 | BMO | 2.86 | 2.95 | +3.1% | 145.20 | -4.4% | -4.3% | +2.1% | -0.5% | +0.9% | +0.6% | — |
| Jul 27, 2023 | BMO | 2.79 | 2.91 | +4.3% | 141.90 | +1.8% | +4.9% | +1.3% | -0.8% | -0.7% | +0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Guggenheim | Maintains | Buy → Buy | — | $211.32 | $211.00 | -0.2% | -2.2% | +0.8% | -1.0% | -0.5% | -1.1% |
| Apr 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $203.89 | $209.00 | +2.5% | +3.6% | -2.2% | +0.8% | -1.0% | -0.5% |
| Apr 30 | Morgan Stanley | Maintains | Overweight → Overweight | — | $203.89 | $209.00 | +2.5% | +3.6% | -2.2% | +0.8% | -1.0% | -0.5% |
| Apr 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $203.89 | $209.00 | +2.5% | +3.6% | -2.2% | +0.8% | -1.0% | -0.5% |
| Apr 30 | BofA Securities | Upgrade | Neutral → Buy | $234 | $203.89 | $209.00 | +2.5% | +3.6% | -2.2% | +0.8% | -1.0% | -0.5% |
| Apr 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $200.50 | $201.05 | +0.3% | +0.2% | -1.1% | -0.7% | +0.2% | +3.1% |
| Apr 21 | Canaccord Genuity | Initiates | Buy | $262 | $203.71 | $204.01 | +0.1% | +0.7% | -2.3% | +0.2% | -1.1% | -0.7% |
| Apr 10 | Guggenheim | Maintains | Buy → Buy | — | $212.40 | $213.55 | +0.5% | -2.1% | -0.7% | +1.8% | -0.9% | +0.3% |
| Apr 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $206.37 | $206.26 | -0.1% | +2.5% | +0.4% | -2.1% | -0.7% | +1.8% |
| Feb 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $232.86 | $234.00 | +0.5% | -1.8% | -1.9% | +0.2% | +2.1% | -0.5% |
| Feb 17 | Freedom Broker | Maintains | Buy → Buy | — | $231.50 | $232.66 | +0.5% | +0.6% | -1.8% | -1.9% | +0.2% | +2.1% |
| Feb 5 | Evercore ISI | Maintains | Outperform → Outperform | — | $217.11 | $216.90 | -0.1% | +0.9% | +2.0% | -0.1% | -0.4% | -0.7% |
| Feb 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $217.11 | $216.90 | -0.1% | +0.9% | +2.0% | -0.1% | -0.4% | -0.7% |
| Feb 5 | UBS | Maintains | Neutral → Neutral | — | $217.11 | $216.90 | -0.1% | +0.9% | +2.0% | -0.1% | -0.4% | -0.7% |
| Jan 27 | Citigroup | Maintains | Neutral → Neutral | — | $220.77 | $220.88 | +0.0% | +1.4% | -2.3% | +0.8% | +1.2% | +1.2% |
| Jan 8 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $233.42 | $231.13 | -1.0% | -4.0% | -1.8% | -0.0% | +0.3% | +0.5% |
| Dec 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $223.98 | $223.69 | -0.1% | -0.3% | +1.8% | -1.7% | +0.3% | -0.7% |
| Dec 10 | HSBC | Upgrade | Hold → Buy | — | $222.99 | $225.00 | +0.9% | +1.0% | -0.5% | -0.3% | +1.8% | -1.7% |
| Nov 12 | Freedom Broker | Maintains | Buy → Buy | — | $225.17 | $225.40 | +0.1% | +3.6% | -0.4% | +0.0% | +0.7% | -0.1% |
| Nov 7 | UBS | Maintains | Neutral → Neutral | — | $219.04 | $219.31 | +0.1% | +0.1% | -0.2% | +3.0% | +3.6% | -0.4% |
| Nov 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $215.89 | $215.74 | -0.1% | +0.4% | +1.0% | +0.1% | -0.2% | +3.0% |
| Nov 3 | Citigroup | Maintains | Neutral → Neutral | — | $218.04 | $216.68 | -0.6% | -2.8% | +1.9% | +0.4% | +1.0% | +0.1% |
| Nov 3 | JP Morgan | Maintains | Overweight → Overweight | — | $218.04 | $216.68 | -0.6% | -2.8% | +1.9% | +0.4% | +1.0% | +0.1% |
| Oct 20 | Guggenheim | Maintains | Buy → Buy | — | $229.57 | $231.00 | +0.6% | +1.1% | -0.3% | -1.2% | -0.2% | -0.1% |
| Oct 17 | Raymond James | Maintains | Outperform → Outperform | — | $226.87 | $227.52 | +0.3% | +1.2% | +1.1% | -0.3% | -1.2% | -0.2% |
| Oct 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $230.69 | $231.51 | +0.4% | -0.1% | -0.1% | -0.5% | -1.3% | +0.3% |
| Oct 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $231.24 | $233.27 | +0.9% | -0.2% | -0.1% | -0.1% | -0.5% | -1.3% |
| Oct 3 | BofA Securities | Maintains | Neutral → Neutral | — | $236.56 | $236.90 | +0.1% | -1.1% | -1.6% | +1.1% | -0.7% | -0.2% |
| Oct 1 | HSBC | Downgrade | Buy → Hold | — | $231.54 | $233.64 | +0.9% | +5.5% | -3.2% | -1.1% | -1.6% | +1.1% |
| Sep 22 | Evercore ISI | Maintains | Outperform → Outperform | — | $222.47 | $222.46 | -0.0% | +0.1% | +0.0% | -1.2% | -0.7% | +0.9% |
| Sep 17 | Berenberg | Upgrade | Hold → Buy | — | $216.26 | $219.10 | +1.3% | +2.1% | +0.5% | +0.2% | +0.1% | +0.0% |
| Sep 16 | JP Morgan | Maintains | Overweight → Overweight | — | $217.61 | $218.33 | +0.3% | -0.6% | +2.1% | +0.5% | +0.2% | +0.1% |
| Sep 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $218.34 | $219.60 | +0.6% | -0.3% | -0.6% | +2.1% | +0.5% | +0.2% |
| Sep 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $220.22 | $219.12 | -0.5% | -0.9% | -0.3% | -0.6% | +2.1% | +0.5% |
| Sep 12 | BMO Capital | Maintains | Outperform → Outperform | — | $220.22 | $219.12 | -0.5% | -0.9% | -0.3% | -0.6% | +2.1% | +0.5% |
| Aug 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $198.64 | $199.76 | +0.6% | +1.4% | +1.6% | +1.0% | -0.1% | -0.2% |
| Aug 1 | Morgan Stanley | Maintains | Overweight → Overweight | — | $189.02 | $189.92 | +0.5% | +3.3% | +1.0% | +0.7% | -1.1% | +1.3% |
| Aug 1 | Raymond James | Maintains | Outperform → Outperform | — | $189.02 | $189.92 | +0.5% | +3.3% | +1.0% | +0.7% | -1.1% | +1.3% |
| Aug 1 | Guggenheim | Maintains | Buy → Buy | — | $189.02 | $189.92 | +0.5% | +3.3% | +1.0% | +0.7% | -1.1% | +1.3% |
| Aug 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $189.02 | $189.92 | +0.5% | +3.3% | +1.0% | +0.7% | -1.1% | +1.3% |
| May 14 | Citigroup | Downgrade | Buy → Neutral | — | $188.00 | $186.52 | -0.8% | -5.6% | +2.4% | +1.3% | +0.9% | -0.5% |
| Apr 29 | Guggenheim | Maintains | Buy → Buy | — | $192.34 | $192.59 | +0.1% | +0.6% | +0.8% | -0.9% | +2.7% | -1.2% |
| Apr 28 | Raymond James | Maintains | Outperform → Outperform | — | $186.06 | $188.00 | +1.0% | +3.4% | +0.6% | +0.8% | -0.9% | +2.7% |
| Apr 28 | Evercore ISI | Maintains | Outperform → Outperform | — | $186.06 | $188.00 | +1.0% | +3.4% | +0.6% | +0.8% | -0.9% | +2.7% |
| Apr 28 | Morgan Stanley | Maintains | Overweight → Overweight | — | $186.06 | $188.00 | +1.0% | +3.4% | +0.6% | +0.8% | -0.9% | +2.7% |
| Apr 28 | BofA Securities | Maintains | Neutral → Neutral | — | $186.06 | $188.00 | +1.0% | +3.4% | +0.6% | +0.8% | -0.9% | +2.7% |
| Apr 21 | BofA Securities | Maintains | Neutral → Neutral | — | $172.99 | $173.47 | +0.3% | -1.6% | +2.1% | +1.8% | +1.9% | +3.2% |
| Apr 17 | Guggenheim | Maintains | Buy → Buy | — | $171.68 | $172.57 | +0.5% | +0.8% | -1.6% | +2.1% | +1.8% | +1.9% |
| Apr 11 | Citigroup | Maintains | Buy → Buy | — | $174.20 | $173.81 | -0.2% | +0.5% | +2.3% | -1.3% | -2.9% | +0.8% |
| Apr 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $175.67 | $168.30 | -4.2% | +2.4% | -3.1% | +0.5% | +2.3% | -1.3% |
No insider trades available.
8-K
ABBVIE INC. -- 8-K Filing
AbbVie's first-quarter 2026 results exceeded expectations with strong performance from growth drivers, prompting the company to raise its full-year guidance.
Apr 29
8-K
Unknown — 8-K Filing
AbbVie provided 2026 guidance with acquired in-process R&D and milestone expenses, signaling continued investment in pipeline assets that could drive future growth but may pressure near-term earnings.
Apr 3
8-K · 8.01
!! High
ABBVIE INC. -- 8-K 8.01: Material Event / Announcement
AbbVie completed a registered debt offering under its Form S-3 registration statement, allowing the company flexible access to capital markets for future issuances.
Mar 4
8-K · 8.01
!! High
ABBVIE INC. -- 8-K 8.01: Material Event / Announcement
AbbVie engaged major underwriters JPMorgan, Bank of America, and Morgan Stanley for a securities offering, likely signaling planned debt or equity issuance to fund operations or acquisitions.
Feb 26
8-K
ABBVIE INC. -- 8-K Filing
AbbVie reported record net sales in its second full year post-Humira exclusivity loss, demonstrating successful portfolio diversification beyond its former blockbuster drug.
Feb 4
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 114,880,324 | $25.0B | New | Mar 2026 |
| 2 | Morgan Stanley | 80,083,880 | $18.3B | Reduced | Dec 2025 |
| 3 | Jpmorgan Chase & Co | 56,741,691 | $12.1B | Added | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 49,523,078 | $10.8B | New | Mar 2026 |
| 5 | Capital Research Global Investors | 31,254,786 | $6.8B | Added | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 23,936,943 | $5.2B | Reduced | Mar 2026 |
| 7 | Fmr Llc | 21,762,703 | $4.7B | Reduced | Mar 2026 |
| 8 | Northern Trust Corp | 21,211,382 | $4.6B | Reduced | Mar 2026 |
| 9 | Capital World Investors | 15,841,367 | $3.4B | Added | Mar 2026 |
| 10 | Franklin Resources Inc | 14,552,069 | $3.2B | Reduced | Mar 2026 |
| 11 | Ubs Group Ag | 14,051,196 | $3.1B | Added | Mar 2026 |
| 12 | Bank Of New York Mellon Corp | 13,278,161 | $2.9B | Reduced | Mar 2026 |
| 13 | Nuveen, Llc | 11,115,159 | $2.4B | Added | Mar 2026 |
| 14 | Amundi | 10,698,095 | $2.3B | New | Mar 2026 |
| 15 | Raymond James Financial Inc | 9,604,349 | $2.1B | Added | Mar 2026 |
| 16 | Wells Fargo & Company/mn | 8,909,597 | $1.9B | New | Mar 2026 |
| 17 | Invesco Ltd. | 7,798,048 | $1.7B | Reduced | Mar 2026 |
| 18 | Royal Bank Of Canada | 7,534,148 | $1.6B | Reduced | Mar 2026 |
| 19 | Janus Henderson Group Plc | 6,931,036 | $1.5B | New | Mar 2026 |
| 20 | State Farm Mutual Automobile Insurance Co | 5,892,808 | $1.3B | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$382.74B
Enterprise Value
$438.65B
P/E (TTM)
91.41x
Forward P/E
15.26x
PEG Ratio
-77.01x
P/B
—
P/S
6.28x
P/FCF
21.57x
EV/EBITDA
24.88x
Shares Out
1.77B
Financials (TTM)
Revenue
$61.16B
Net Income
$4.23B
EBITDA
$17.63B
Free Cash Flow
$17.82B
Op Cash Flow
$19.03B
EPS Basic
$2.37
EPS Diluted
$2.37
EPS Forward
$14.19
Gross Margin
70.2%
Op Margin
32.9%
Net Margin
6.9%
Balance Sheet
Total Assets
$133.96B
Total Liab.
$137.19B
Total Equity
-$3.23B
Cash
$5.26B
LT Debt
$59.61B
Book Value/Sh
$-1.81
Debt/Equity
-21.12x
Current Ratio
0.67
Quick Ratio
0.56
Returns & Growth
ROE
-55.5%
ROA
1.4%
ROIC
13.0%
Rev Growth YoY
+8.6%
EPS Growth YoY
-1.2%
Price Returns
2W
+3.3%
1M
+3.0%
3M
-6.2%
6M
-4.4%
12M
+16.9%
Technicals
52W High
$244.81
52W Low
$181.73
50d MA
$211.67
200d MA
$220.54
RSI (14)
48.70
ATR (14)
$5.23
Beta
0.36
Avg Volume
5.5M
Dividends
Div Rate
$6.55
Div Yield
3.2%
Frequency
4
Ex-Div Date
Apr 15, 2026
Analyst Price Targets
Consensus
$256.64
High
$294.00
Low
$223.00
Median
$259.00
Data updated apr 24, 2026 10:11am
· Source: financialmodelingprep.com